Used as a key intermediate in the synthesis of tyrosine kinase inhibitors, particularly in targeted cancer therapies. It plays a role in the development of compounds that inhibit abnormal signaling pathways in tumor cells, especially in non-small cell lung cancer and other solid tumors. Its structure enables selective binding to mutant forms of epidermal growth factor receptor (EGFR), making it valuable in creating drugs with improved efficacy and reduced side effects. Also employed in research settings to explore new oncology treatments and structure-activity relationships in kinase inhibitor design.